Blood test offers hope for more effective ovarian cancer treatment
More than 300,000 women are diagnosed with ovarian cancer globally each year.
The four-year clinical trial across 15 Australian hospitals – known as SOLACE2 – was co-led by the University of Sydney NHMRC Clinical Trials Centre, RMIT University and WEHI, and coordinated by the Australia New Zealand Gynaecological Oncology Group (ANZGOG).
The Phase II trial tested strategies for priming the immune system to enhance the effectiveness of PARP inhibitor therapy, which stops cancer cells from repairing their own damaged DNA by blocking the PARP enzyme.
It was during this trial that a new companion blood test for women with ovarian cancer was also ...